World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Tel. direct: +41 22 791 3927
Fax direct: +41 22 791 4836
Email: diagnostics@who.int

In reply, please refer to: CC/sh

Your reference: P17-370-9

Premier Medical Corporation Private Limited
Attention: Dr Rajeshkumar Patel
Director and Technology Head
A1-302/ GIDC
Sarigam, Dist.
Valsad 396 155
Inde

10 April 2024

Dear Dr Patel,

Subject: WHO Prequalification of In Vitro Diagnostics – Amended Final Public Report

Product name: First Response HIV 1+2/Syphilis Combo Card Test
Product codes: I20FRC25, I20FRC30, I20FRC50, I20FRC60, I20FRC100 and I20FRC25-SA.
Regulatory version: Rest of World
Manufacturer: Premier Medical Corporation Private Limited
PQDx Reference Number: PQDx 0364-010-00

We are pleased to inform you that the prequalification public report for the above-referenced product was amended on 27 March 2024. The public report was amended due to the addition of performance evaluation results for HIV subtypes.

The following post-prequalification activities are required to maintain the prequalification status:

1. Notification to WHO of any planned changes to a prequalified product, in accordance with "WHO procedure for changes to a WHO prequalified in vitro diagnostic" (document number PQDx_121); and

2. Post-market surveillance activities, in accordance with "Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics" (ISBN 978-92-4-001531-9).

You are also required to submit an annual report that details sales data and all categories of complaints in a summarized form. There are certain categories of complaints and changes to the product that must be notified immediately to WHO, as per the above-mentioned documents. The sales data will serve as denominator data to guide the frequency of re-inspection.

ENCL: (1)

Failure to comply with any of the above-mentioned post-prequalification requirements may lead to remedial action by the WHO, including but not limited to de-listing from the WHO list of prequalified in vitro diagnostic products.

If you have any questions, please do not hesitate to contact us by email (diagnostics@who.int) or telephone (+4122 791 3927).

Yours sincerely,

Dr Rogério Gaspar
Director
Regulation and Prequalification Department
(as acting Unit Head, Prequalification Unit)